Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo: Characterisation of drugs with an increased benefit-risk ratio

BioDrugs

Volumn 13, Issue 4, 2000, Pages 267-277

  Schackert, Carolin ^a   Korting, Hans Christian ^a   Schäfer Korting, Monika ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CORTICOSTEROID; DESOXIMETASONE; FLUOCINOLONE ACETONIDE; FLUOCORTIN BUTYL; FLUOCORTOLONE; HALOMETASONE; HYDROCORTISONE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PREDNICARBATE; PREDNISOLONE; TRIAMCINOLONE ACETONIDE;

ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CORTICOSTEROID THERAPY; CUSHING SYNDROME; CYTOKINE RELEASE; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SKIN ATROPHY; SKIN DISEASE;

EID: 0034060686     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013040-00005     Document Type: Review

References (69)

1. 1. Schäfer-Korting M, Schmid MH, Korting HC. Topical glucocorticoids with improved risk-benefit ratio: rationale of a new concept. Drug Saf 1996; 14: 375-85
2. 2. Epstein NN, Epstein WL, Epstein JH. Atrophic striae in patients with inguinal intertrigo. Arch Dermatol 1963; 87: 450-7
3. 3. Marks R. Adverse side effects from the use of topical corticoids. In: Maibach HI, Surber C, editors. Topical corticosteroids. Basel: Karger, 1992: 170-83
4. 4. Korting HC, Vieluf D, Kerscher M. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1 % betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 1992; 42: 159-61
5. 5. Schäfer-Korting M, Korting HC, Kerscher MJ, et al. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 1993; 54: 448-56
6. 6. Korting HC, Kerscher MJ, Schäfer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 1992; 27: 87-92
7. 7. Ponec M, Kempenaar J, Shroot B, et al. Glucocorticoids: binding affinity and lipophilicity. J Pharm Sci 1986; 75: 973-5
8. 8. Rohdewald P, Möllmann HW, Hochhaus G. Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents Actions 1986; 17: 290-1
9. 9. Lange K, Gysler A, Bader M, et al. Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. Pharm Res 1997; 14: 1744-9
10. 10. Gysler A, Kleuser B, Sippl W, et al. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res 1999; 16: 1386-91
11. 11. Gysler A, Lange K, Korting HC, et al. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997; 14: 793-7
12. 12. Barth J, Lehr KH, Derendorf H, et al. Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. Skin Pharmacol 1993; 6: 179-86
13. 13. Barth J, Hochaus G, Derendorf H, et al. Prednicarbate after different forms of administration: plasma levels of drug and metabolites and effects on endogenous cortisol levels in humans. In: Korting HC, Maibach HI, editors. Topical glucocorticoids with increased benefit/risk ratio. Basel: Karger, 1993: 147-56
14. 14. Lippert U, Welker P, Kruger-Krasagakes S, et al. Modulation of in vitro cytokine release from human leukemic mast cells (HMC-1) by glucocorticoids. Skin Pharmacol 1996; 9: 93-8
15. 15. Crocker IC, Zhou CY, Bewtra AK, et al. Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol 1997; 78: 497-505
16. 16. Göttlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 1998; 76: 480-9
17. 17. Lange K, Gysler A, Bader M, et al. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol. In press
18. 18. Barton BE, Jakway JP, Smith SR, et al. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991; 13: 251-61
19. 19. Michel G, Nowok K, Beetz A, et al. Novel steroid derivative modulates gene expression of cytokines and growth regulators. Skin Pharmacol 1995; 8: 215-20
20. 20. Prakash A, Benfield P. Topical mometasone: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998; 55: 145-63
21. 21. Korting HC, Hülsebus E, Kerscher M, et al. Discrimination of the toxic potential of chemically differing topical glucocorticoids using a neutral red release assay with human keratinocytes and fibroblasts. Br J Dermatol 1995; 133: 54-9
22. 22. Gormar FE, Bernd A, Holzmann H. The effect of hydrocortisone aceponate on proliferation, total protein synthesis and collagen synthesis in human skin fibroblasts in vitro. Arzneimittelforschung 1990; 40: 192-6
23. 23. Hein R, Mauch C, Hatamochi A, et al. Influence of corticosteroids on chemotactic response and collagen metabolism of human skin fibroblasts. Biochem Pharmacol 1988; 37: 2723-9
24. 24. Hein R, Korting HC, Mehring T. Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol 1994; 7: 300-6
25. 25. Grotendorst GR, Martin G. Cell movements in wound healing and fibrosis. In: Kühn K, Krieg T, editors. Cutaneous connective tissue. Basel: Karger, 1986: 385-403
26. 26. Wach F, Bosserhoff A, Kurzidym U, et al. Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol 1998; 11: 43-51
27. 27. Vogel HG, Petri W. Comparison of various pharmaceutical preparations of prednicarbate after repeated topical administration to the skin of rats. Arzneimittelforschung 1985; 35: 939-46
28. 28. Zentel HJ, Töpert M. Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate. J Eur Acad Dermatol Venereol 1994; 3 Suppl. 1: 32-8
29. 29. Kimura M, Tarumoto Y, Nakane S, et al. Comparative toxicity study of hydrocortisone 17-butyrate 21-propionate (HBP) ointment and other topical corticosteroids in rats. Drugs Exp Clin Res 1986; 12: 643-52
30. 30. Lubach D, Kietzmann M. Investigation of the skin thinning effect of prednicarbate and other corticoids in mouse skin. Skin Pharmacology 1988; 1: 200-6
31. 31. McKenzie A, Stoughton R. Methods for comparing percutaneous absorption of steroids. Arch Dermatol 1962; 86: 608-10
32. 32. Ljunggren B, Möller H. Influence of corticosteroids on ultraviolet light erythema and pigmentation in man. Arch Dermatol Forsch 1973; 248: 1-12
33. 33. Schalla W, Schorning S. Potency assessment of topical corticoids in the vasoconstrictor assay and on tuberculin-induced inflammation. Skin Pharmacol 1991; 4: 191-204
34. 34. Kecskes A, Jahn P, Wendt H, et al. Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers. Arzneimittelforschung 1993; 43: 144-7
35. 35. Spencer C, Wagstaff A. Prednicarbate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs 1998; 9: 61-86
36. 36. Hanifin J, Abrams B, Cherill R. Management of atopic dermatitis with prednicarbate emollient cream 0.1 %, a non-halogenated prednisolone derivative. J Geriatr Dermatol 1994; 2: 119-27
37. 37. Ulrich R, Anderson I. Double-blind comparative trial involving 0.5% halomethasone (Sicorten®) cream versus 0.25 %, prednicarbate cream in patients with acute episodes of atopic dermatitis. Fortschr Med 1991; 109: 741-44
38. 38. Vogt HJ, Höhler T. Controlled studies of intraindividual and interindividual design for comparing corticosteroids clinically. In: Christophers E, Schopf E, Keigman AM, et al., editors. Topical corticosteroid therapy: a novel approach to safer drugs. New York (NY): Raven Press; 1988: 169-79
39. 39. Lawlor F, Black AK, Greaves M. Prednicarbate 0.25% ointment in the treatment of atopic dermatitis: a vehicle-controlled double-blind study. J Dermatol Treat 1995; 6: 233-5
40. 40. Aliaga A, Rodriguez M, Armijo M, et al. Double-blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis. Int J Dermatol 1996; 35: 131-2
41. 41. Nolting S, Glowania HJ, Gründer K, et al. Treatment of atopic eczema in childhood: results of a controlled trial with topical corticosteroid preparations mometasone and prednicarbate [in German]. Kinderarztl Prax 1991; 22: 1691-4
42. 42. Schulz H, Maue R, Meyer-Latzke E. Topical use of prednicarbate preparations in children [in German]. Z Hautkr 1986; 61 Suppl. 1: 41-50
43. 43. Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis 1988; 42: 480-5
44. 44. Bjerring P. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser doppler blood flowmetry. Skin Pharmacol 1993; 6: 187-92
45. 45. Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther 1997; 19: 710-9
46. 46. Rampini E. Methylprednisolone aceponate (MPA): use and clinical experience in children. J Dermatol Treat 1992; 2 (3 Suppl.): 27-9
47. 47. Fritsch P. Clinical experience with methylprednisolone aceponate (MPA) in eczema. J Dermatol Treat 1992; 2 (3 Suppl.): 17-9
48. 48. Bjerke JR, Gjertsen BT, Peterson LE. Prednicarbate (Dermatop) compared w ith desoximethasone (Ibaril): a double-blind clinical trial of a non-halogenated corticosteroid in 57 patients with psoriasis. Clin Trials J 1990; 27: 94-9
49. 49. Iglesias L, Guerra A, Ledo A, et al. Resultados de un ensayo clinico comerativo intraindividual, aleatorizado y doble ciego entre dos corticoides topicos, prednicarbato y diflucortolona en el tratamiento de la psoriasis [abstract no. 442]. XXIII National Congress of Dermatology and Venerology: 1994; Madrid
50. 50. Tan CY, Marks R, Payne P. Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J Invest Dermatol 1981; 76: 126-8
51. 51. Kerscher M, Korting HC. Assessment of the atrophogenicity potential of chemically different potent topical glucocorticoid derivatives by high frequency ultrasound. Eur J Dermatol 1992; 2: 440-2
52. 52. Korting HC. Topical glucocorticoids and thinning of normal skin as assessed by ultrasound. Curr Probl Dermatol 1993; 21: 114-21
53. 53. Mills CM, Marks R. Side effects of topical glucocorticoids. In: Korting HC, Maibach HI, editors. Topical glucocorticoids with increased benefit/risk ratio. Basel: Karger, 1993: 122-31
54. 54. Kerscher MJ, Korting HC. Topical glucocorticoids of the nonfluorinated double-ester type: lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol 1992; 72: 214-6
55. 55. Kerscher MJ, Hart H, Korting HC, et al. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995; 33: 187-9
56. 56. Ernst TM. Reaction of autogenous cortisol production in patients with extensive psoriasis vulgaris or atopic dermatitis following external administration of a 0.25% prednicarbate salve (W/O emulsion). Z Hautkr 1986; 61 Suppl. 1: 74-9
57. 57. Albrecht G. Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema. J Eur Acad Dermatol Venereol 1994; 3 Suppl. 1: 42-8
58. 58. Dunkel FG, Elsner P, Burg G. Contact allergies to topical corticosteroids: 10 cases of contact dermatitis. Contact Dermatitis 1991; 25: 97-103
59. 3. Br J Pharmacol 1994; 113: 439-44
60. 60. Levy J, Gassmüller J, Schroder G, et al. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. Skin Pharmacol 1994; 7: 231-6
61. 61. Kligman LH, Schwartz E, Lesnik RH, et al. Topical tretinom prevents corticosteroid-induced atrophy without lessening the anti-inflammatory effect. Curr Probl Dermatol 1993; 21: 79-88
62. 62. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996; 135: 60-4
63. 63. Tramposch KM. Combination of a dual 5-lipoxygenase/ cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy. Inflammation 1993; 17: 531-6
64. 64. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis: European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816-21
65. 65. Palminteri R. Benefit/risk ratio of new drugs: for whom? [discussion paper]. J R Soc Med 1988; 81: 155-7
66. 66. Hasford J, Victor N. Risk-benefit analyses of drugs: fundamental considerations and requirements from the point of view of the biometrician: problems in the assessment of the combination of trimethoprim with sulfamethoxazole. Infection 1987; 15 Suppl. 5: S236-40
67. 67. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids: American Academy of Dermatology. J Am Acad Dermatol 1996; 35: 615-9
68. 68. Bigby M. Evidence-based medicine in a nutshell: a guide to finding and using the best evidence in caring for patients. Arch Dermatol 1998; 134: 1609-18
69. 69. Williams H, Adetugbo K, Po AL, et al. The Cochrane Skin Group: preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology. Arch Dermatol 1998; 134; 1620-6